Fine-tuning ALK1 linear polyubiquitination to control angiogenesis.


Journal

Trends in cell biology
ISSN: 1879-3088
Titre abrégé: Trends Cell Biol
Pays: England
ID NLM: 9200566

Informations de publication

Date de publication:
09 2021
Historique:
received: 19 07 2021
revised: 19 07 2021
accepted: 19 07 2021
pubmed: 1 8 2021
medline: 15 12 2021
entrez: 31 7 2021
Statut: ppublish

Résumé

Editing linear polyubiquitination of protein substrates by LUBAC and OTULIN is known to play a critical role in immune responses. A recent study by Fu et al. reveals how reversible linear polyubiquitination of the activin receptor-like kinase (ALK1) controls developmental angiogenesis and how its dysfunction leads to vascular malformations in humans.

Identifiants

pubmed: 34330579
pii: S0962-8924(21)00144-6
doi: 10.1016/j.tcb.2021.07.004
pii:
doi:

Substances chimiques

Activin Receptors, Type II EC 2.7.11.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

705-707

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Peter Ten Dijke (P)

Oncode Institute and Cell Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: P.ten_dijke@lumc.nl.

David Baker (D)

Oncode Institute and Cell Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH